Formulation Development
Finch Therapeutics Announces Positive Topline Data From Phase 2 PRISM-EXT Open-Label Study of Microbiome Therapy for Recurrent C. diff.
Finch Therapeutics Group, Inc. recently announced positive topline results from PRISM-EXT, an open-label extension of the company’s PRISM3 Phase 2 placebo-controlled trial evaluating CP101 for…
Mustang Bio Announces Exclusive Worldwide License Agreement With Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy With Curative Potential for RAG1 Severe Combined Immunodeficiency
Mustang Bio, Inc. recently announced that the company has executed an exclusive license agreement with Leiden University Medical Centre (LUMC) for a first-in-class ex vivo lentiviral gene therapy for the….
Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients With Parkinson’s Disease
Yumanity Therapeutics recently reported its lead product candidate, YTX-7739, in development for the treatment of Parkinson’s disease, achieved its primary endpoints in a randomized, placebo-controlled…
CN Bio & iiCON Announce COVID-19 Research Collaboration
CN Bio recently announced a research collaboration with the Infection Innovation Consortium (iiCON), a global collaborative infectious disease R&D program, to validate the next-generation of…
Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) of Milademetan
Rain Therapeutics Inc. recently announced its plan to commence a Phase 2 clinical trial, named MANTRA-3, evaluating the efficacy of milademetan, an oral mouse double…
Synlogic & Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine for the Treatment of Homocystinuria
Synlogic, Inc. and Ginkgo Bioworks recently announced the nomination of SYNB1353, an investigational Synthetic Biotic medicine for the treatment of homocystinuria (HCU). SYNB1353 is the…
Eton Pharmaceuticals & Azurity Pharmaceuticals, Inc. Announce FDA Approval of EPRONTIA Oral Solution
Eton Pharmaceuticals, Inc and Azurity Pharmaceuticals, Inc. recently announced the US FDA has approved EPRONTIA (topiramate) oral solution, 25 mg/mL. EPRONTIA has been approved as…
Cocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity Against Human Common Coronaviruses, Noroviruses, Rhinoviruses & Enteroviruses
Cocrystal Pharma, Inc. recently announced that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral activity against human common coronaviruses, rhinoviruses, and respiratory enteroviruses…
TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma Patients
TFF Pharmaceuticals, Inc. recently announced the completion of dosing in the Phase 1b clinical trial of Voriconazole Inhalation Powder (TFF VORI), a next-generation, direct-to-lung, inhaled…
PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate & Breast Cancers From National Cancer Institute
PDS Biotechnology Corporation recently announced a licensing agreement with the National Cancer Institute (NCI) for intellectual property related to the NCI’s proprietary tumor-associated and immunologically active…
PDC* line Pharma Opens Last Cohort of PDC-Lung-101 Clinical Trial
PDC*line Pharma recently announced the last cohort of patients has been opened and the first patients were dosed, in the PDC-LUNG-101 Phase 1/2 clinical trial (NCT03970746) with PDC*lung01, the company’s therapeutic cancer….
Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial
Longeveron Inc. recently announced the selection of Biorasi LLC as its clinical research organization (CRO) to help conduct its Phase 2 clinical trial evaluating Lomecel-B…
Nemera Reinforces its Value Proposition With a Refreshing Visual Identity
More modern, our new brand identity truly embodies who we are, how we partner with our customers and ultimately the value we bring to millions…
XOMA Earns $35-Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer
XOMA Corporation recently announced NIS793, an anti-TGFβ monoclonal antibody licensed from the company, has advanced to the Phase 3 development stage, triggering a $35-million milestone…
Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia
Eyenovia, Inc. recently announced the first patient has been enrolled in the company’s second Phase 3 clinical trial of MicroLine, its proprietary pilocarpine formulation for…
Zealand Pharma Announces First Subject Dosed in Phase 1 Trial of Amylin Analogue ZP8396 for the Treatment of Obesity
Zealand Pharma A/S recently announced the first patient has been dosed in a Phase 1 clinical trial evaluating the amylin analogue, ZP8396 as a potential…
Processa Pharmaceuticals Announces Next- Generation Capecitabine Inhibits DPD in Phase 1b Interim Analysis
Processa Pharmaceuticals, Inc. recently announced the company’s Next-Generation Capecitabine dosage regimen (a combination of PCS6422 administered with capecitabine) successfully inhibited dihydropyrimidine dehydrogenase (DPD), altering the…
Centogene Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases
Centogene N.V. recently announced it has expanded its partnership with Agios Pharmaceuticals, Inc to provide genetic testing and clinical trial support for Agios’ three global,…
ESCP Models - Hepatitis C Medications (Part 2), Oral Therapeutics
Part 2 of this series fills in the story starting with the first oral HCV therapeutic, Vertex’s Incivek (telaprevir), which predated the first of the Gilead therapeutics by 2.5 years…
Allena Pharmaceuticals Receives Fast Track Designation From FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout & Advanced Chronic Kidney Disease
Allena Pharmaceuticals, Inc. recently announced its orally administered, urate-degrading enzyme, ALLN-346, has received Fast Track designation from the US FDA. ALLN-346 is in Phase 2…
